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Cross-reactive  
Antibodies against  
Avian Influenza  
Virus A (H5N1)
To  the  Editor:  Intravenous  im-
munoglobulin (IVIg) is used to treat 
bacterial  and  viral  infections  in  pa-
tients with primary immunodeficiency 
disease  and  those  with  autoimmune 
and inflammatory disorders (1). IVIg 
contains  pooled  IgG  from  >1,000 
blood  donors  and  antibodies  against 
various  common  human  pathogens, 
including influenza virus A.
We tested the efficacy of commer-
cial preparations of IVIg (50 mg/mL 
of  highly  purified  immunoglobulin) 
against homosubtypic influenza virus-
es A (H1N1 and H3N2) and their cross-
reactivity against avian influenza virus 
A (H5N1). IVIg preparations  (Octag-
am; Octapharma, Vienna, Austria and 
Flebogamma;  Instituto  Grifols,  Bar-
celona,  Spain)  had  hemagglutination 
inhibition (HI) titers against subtypes 
H1N1 and H3N2 ranging from 20 to 
40. Human Immunoglobulin, pH 4.0, 
(Harbin Sequel Bio-Engineering Phar-
maceutical, Harbin, People’s Republic 
of China) had lower HI titers against 
avian influenza viruses (10 for subtype 
H3N2 and <10 for subtype H1N1). As 
expected, we did not detect antibodies 
against  hemagglutinin  (HA)  of  sub-
type H5N1 (A/open-billed/stork/Nah-
konsawan/BBD0104F/2004) in any of 
the IVIg preparations (HI titer <10).
Human influenza subtype H1N1 
shares the same neuraminidase (NA) 
subtype  (human  N1)  as  subtype 
H5N1 (avian N1). We therefore tested 
whether IVIg preparations would re-
act and inhibit NA activity of human 
and avian influenza viruses by using 
a neuraminidase inhibition (NI) assay 
(2). NI titer was defined as the recip-
rocal of the highest dilution that gave 
50% reduction compared with that of 
the virus control.
All 3 IVIg preparations inhibited 
NA  activity  of  human  N1  (NI  titer 
against  subtype  H1N1  range  258–
986) and human N2 (NI titer against 
subtype  H3N2  range  1,309–3,274). 
Enzyme  activity  of  avian  N1  (7:1 
reassortant; PR8 + NA [A/Vietnam/ 
DT-0361/2005  H5N1])  was  inhib-
ited by all IVIg preparations (NI titer 
range 143–231). These findings sup-
port the recent observation of neutral-
izing antibodies against human N1 in 
human  serum,  which  could  inhibit 
enzyme  activity  of  avian  N1  from 
subtype H5N1 (3,4). We also tested 
IVIg preparations against reverse ge-
netics subtype H5N3 virus in which 
the N3 NA was derived from H2N3 
virus  (6:1:1  reassortant;  6  internal 
genes from PR8 + HA (A/Vietnam/
DT-0361/05  H5N1)  +  NA  (A/duck/
Germany 1207 H2N3) and observed 
no effect (NI titer <10). The N3 sub-
type belongs to avian influenza NA. 
Thus, antibodies against NA in IVIg 
appear to be specific for those circu-
lating human influenza viruses (hu-
man N1 and human N2).
Unlike HA and NA, virus matrix 
2  ectodomain  (M2e)  is  highly  con-
served. Its presence on the surface of 
the viral particle makes it a potential 
target of antibody response similar to 
that for HA and NA (5,6). We assessed 
reactivity of IVIg preparations against 
a  consensus  M2e  peptide  derived 
from human influenza viruses of H1, 
H2, and H3 subtypes (MSLLTEVET-
PIRNEWGCRCNDSSD)  and  those 
derived  from  A/Hong  Kong/156/97 
H5N1  (MSLLTEVETLTRNGWGCR 
CSDSSD and A/Thailand/ SP-83/2004 
H5N1  (MSLLTEVETPTRNEWECR 
CSDSSD) by using ELISA (7). Anti-
body titer was defined as the recipro-
cal of the highest dilution that had an 
optical density of 0.5 at 414 nm in our 
assay.
Results  showed  considerable 
variation  among  IVIg  preparations, 
caused by M2e peptides derived from 
different influenza viruses (titer range 
88–23,614). Among the 3 preparations, 
Human  Immunoglobulin,  pH  4.0, 
IVIg showed the highest titers against 
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all  M2e  peptides  (consensus,  9,639; 
H5N1 Hong Kong, 3,519; and H5N1 
Thailand,  23,614). Variation  of  anti-
body titers against M2e in IVIGs may 
be geographically dependent. Unlike 
Octagam  and  Flebogamma,  Human 
Immunoglobulin,  pH  4.0,  IVIg  was 
likely  derived  from  blood  donors  in 
China. Octagam and Immunoglobulin, 
pH 4.0, IVIg were more reactive with 
M2e of avian influenza virus (H5N1) 
(A/Thailand/SP-83/2004)  than  with 
other M2e peptides.
We measured the ability of IVIg 
preparations to inhibit influenza sub-
type  H5N1  replication  by  using  a 
plaque-reduction  assay.  Subtype 
H5N1 (A/open-billed stork/ Nakhon-
sawan/BBD0104F/2004)  was  main-
tained as described (8). MDCK cells 
were  infected  with  virus  and  agar 
containing  various  concentrations  of 
IVIg was layered on top of these cells 
and incubated for 2 days. Results are 
shown in the Figure. IVIG inhibited 
plaque formation in a dose-dependent 
manner. Although plaques of hetero-
geneous size were observed in infect-
ed plates without IVIg, larger plaques 
were  preferentially  neutralized  with 
increasing  concentrations  of  IVIg  in 
the agar (Figure).
Premixing  excess  M2e  peptide 
with  IVIg  to  absorb  M2e-specific 
antibodies  had  no  effect  on  plaque 
formation,  indicating  that  antibod-
ies against M2e in IVIg preparations 
were not responsible for neutralization 
of influenza subtype H5N1. Antibod-
ies against M2e may have a role in 
protection  against  subtype  H5N1  by 
another mechanism.
Our data suggest that the neutral-
izing  activity  against  influenza  sub-
type H5N1 in all 3 IVIg preparations 
was likely contributed by cross-reac-
tive antibodies against avian N1. IVIg 
has been reported to have antiinflam-
matory  activity  (9,10).  The  immune 
suppressive effect of IVIg may ben-
efit patients by reducing the cytokine 
storm. These data suggest use of IVIg, 
especially  preparations  containing 
high neutralizing activity against sub-
type  H5N1,  as  adjunctive  treatment 
for  infection  with  highly  pathogenic 
avian influenza virus (H5N1).
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Figure.	Neutralization	of	avian	influenza	virus	A	(H5N1)	by	intravenous	immunoglobulin	(IVIg)	preparations	measured	by	percentage	
reduction	in	plaque	number	(A)	and	plaque	size	(B).	Monolayers	of	MDCK	cells	were	infected	with	virus	and	overlaid	with	agar	containing	
various	concentrations	of	IVIg.	After	2	days,	plaques	were	detected	by	staining	with	crystal	violet.	Shown	is	a	sample	of	viral	plaques	with	
agar	overlay	containing	different	dilutions	(1:50–1:800)	of	Human	Immunoglobulin,	pH	4.0,	(Harbin	Sequel	Bio-Engineering	Pharmaceutical,	
Harbin,	People’s	Republic	of	China)	IVIg	(C).	Data	are	mean	±	SE	of	3	experiments.	A	color	version	of	this	figure	is	available	online	(www.
cdc.gov/EID/content/15/9/1537-F.htm).LETTERS
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